These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 20606183)

  • 21. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-28. PubMed ID: 21374839
    [No Abstract]   [Full Text] [Related]  

  • 23. A few specialty drug prices fall--all generics.
    Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
    [No Abstract]   [Full Text] [Related]  

  • 24. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
    Alifrangis C; Krell J; Stebbing J
    Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmaceutical industry.
    Lewis L
    State Health Care Am; 1994; ():23-7. PubMed ID: 10133845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Affordability of health insurance to small business: implications of the Patient Protection and Affordable Care Act.
    Miller EA
    J Health Polit Policy Law; 2011 Jun; 36(3):539-46. PubMed ID: 21673260
    [No Abstract]   [Full Text] [Related]  

  • 27. 2012--a watershed election for health care.
    Blumenthal D
    N Engl J Med; 2011 Dec; 365(22):2047-9. PubMed ID: 22129250
    [No Abstract]   [Full Text] [Related]  

  • 28. Federalism and the Patient Protection and Affordable Care Act of 2010: the Founding Fathers would not be surprised.
    Sparer MS
    J Health Polit Policy Law; 2011 Jun; 36(3):461-8. PubMed ID: 21673246
    [No Abstract]   [Full Text] [Related]  

  • 29. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 30. Reforming health care reform in the 112th Congress.
    Antos JR
    N Engl J Med; 2011 Jan; 364(1):1-3. PubMed ID: 21142530
    [No Abstract]   [Full Text] [Related]  

  • 31. The political challenges that may undermine health reform.
    Skocpol T
    Health Aff (Millwood); 2010 Jul; 29(7):1288-92. PubMed ID: 20606175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The implementers get down to work.
    Iglehart JK
    Health Aff (Millwood); 2010 Jul; 29(7):1285-7. PubMed ID: 20606174
    [No Abstract]   [Full Text] [Related]  

  • 33. Interest-group influence on the Patient Protection and Affordability Act of 2010: winners and losers in the health care reform debate.
    Quadagno J
    J Health Polit Policy Law; 2011 Jun; 36(3):449-53. PubMed ID: 21673244
    [No Abstract]   [Full Text] [Related]  

  • 34. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 35. "Dear states, healthcare reform is now up to you".
    Reiboldt M
    J Med Pract Manage; 2011; 26(6):329-30. PubMed ID: 21815544
    [No Abstract]   [Full Text] [Related]  

  • 36. Health reform: the politics of implementation.
    Kersh R
    J Health Polit Policy Law; 2011 Jun; 36(3):613-23. PubMed ID: 21673274
    [No Abstract]   [Full Text] [Related]  

  • 37. The states' role under the Patient Protection and Affordable Care Act.
    Greer SL
    J Health Polit Policy Law; 2011 Jun; 36(3):469-73. PubMed ID: 21673247
    [No Abstract]   [Full Text] [Related]  

  • 38. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 39. Behavioral health and health care reform.
    Mechanic D
    J Health Polit Policy Law; 2011 Jun; 36(3):527-31. PubMed ID: 21673258
    [No Abstract]   [Full Text] [Related]  

  • 40. CMS retreats on Part D rule intended to reduce drug costs and improve access.
    Dickson V
    Mod Healthc; 2014 Mar; 44(11):10. PubMed ID: 24830094
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.